ArticleBMC primary care2026
Attitudes of Swedish primary care physicians toward GLP-1 receptor agonists for overweight and obesity: a cross-sectional survey.
Article in BMC primary care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObesity is a growing global health burden, previously with few effective treatments. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were originally approved for diabetes but are increasingly prescribed for treatment of overweight and obesity. The increasing expenditure has led to ethical debates surrounding the utilization of these drugs. Few studies have investigated the attitudes to GLP-1 RAs among prescribing physicians. This study aimed to assess the attitudes to GLP-1 RAs for treatment of overweight and obesity among Swedish primary care physicians.
methodsThis was a cross-sectional survey with descriptive quantitative analysis and thematic analysis of free-text responses. A mix of multiple-choice questions and rating scales, including the Likert scale was employed. The study was conducted in October 2024 among physicians working in primary care in the Swedish regions of Gävleborg, Uppsala, Västernorrland, Västmanland and Örebro. The survey was distributed through the Drug and Therapeutics Committees (DTCs) in the regions.
resultsThe 190 responses yielded a response rate of 28%. Of these, 163 responses could be included in the final analysis. Almost all respondents (98%) agreed that GLP-1 RAs are effective drugs for treating obesity, and 91% believed they will be important for obesity treatment in the future. Main identified barriers for prescribing GLP-1 RAs were high patient co-payment (69%) and low drug availability due to supply shortages at the time of conducting this survey (86%).
conclusionPhysicians working in primary care in Sweden consider GLP-1 RAs effective for treating obesity and believe these drugs will play an important role in obesity treatment in the future. These findings should be interpreted in the light of the low response rate and possible self-selection bias.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.